Zacks Research Analysts Lower Earnings Estimates for Hologic

Hologic, Inc. (NASDAQ:HOLX) – Analysts at Zacks Research lowered their Q4 2025 earnings estimates for Hologic in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $1.12 per share for the quarter, down from their prior forecast of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s FY2027 earnings at $4.97 EPS.

Several other equities analysts also recently issued reports on the company. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Morgan Stanley reduced their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Trading Down 1.8 %

Hologic stock opened at $60.80 on Monday. The stock has a 50-day moving average of $65.70 and a two-hundred day moving average of $73.66. The stock has a market cap of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic has a one year low of $60.34 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. lifted its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares in the last quarter. Brooklyn Investment Group boosted its stake in Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 145 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the period. Finally, Loomis Sayles & Co. L P grew its position in Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 183 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.